Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma

by Benzinga Staff
January 20, 2012 2:45 PM | 18 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Exelixis, Inc. (NASDAQ: EXEL) today reported positive preliminary data from thecohort of hepatocellular carcinoma patients participating in the ongoingphase 2 randomized discontinuation trial of cabozantinib. Allan LeeCohn, M.D., Medical Director of Research at the Rocky Mountain Cancer Centers,will present the data today at 11:45 a.m. PST as part of the 2012Gastrointestinal Cancers Symposium. The meeting is takingplace in San Francisco, California.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.